BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33359128)

  • 1. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
    Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
    Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 DNA hypermethylation in primary gastric tumors; as a novel diagnostic biomarker.
    Amini M; Ghorban K; Mokhtarzadeh A; Dadmanesh M; Baradaran B
    Life Sci; 2020 Aug; 254():117774. PubMed ID: 32407843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZNF677 downregulation by promoter hypermethylation as a driver event through gastric tumorigenesis.
    Bidar N; Rezaei T; Amini M; Jebelli A; Mokhtarzadeh A; Baradaran B
    Exp Mol Pathol; 2021 Aug; 121():104663. PubMed ID: 34171355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
    Micevic G; Thakral D; McGeary M; Bosenberg MW
    Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of FAT4 contributes to gastric field cancerization.
    Yoshida S; Yamashita S; Niwa T; Mori A; Ito S; Ichinose M; Ushijima T
    Gastric Cancer; 2017 Jan; 20(1):136-145. PubMed ID: 26792292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation and expression of TIMP3 gene in gastric cancer.
    Guan Z; Zhang J; Song S; Dai D
    Diagn Pathol; 2013 Jul; 8():110. PubMed ID: 23819566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
    Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
    Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array.
    Fang WL; Chen MH; Huang KH; Chang SC; Lin CH; Chao Y; Lo SS; Li AF; Wu CW; Shyr YM
    Clin Epigenetics; 2019 Nov; 11(1):154. PubMed ID: 31675985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
    Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
    Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
    Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
    Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation signatures associated with prognosis of gastric cancer.
    Dai J; Nishi A; Li ZX; Zhang Y; Zhou T; You WC; Li WQ; Pan KF
    BMC Cancer; 2021 May; 21(1):610. PubMed ID: 34034702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker.
    Raja UM; Gopal G; Rajkumar T
    Asian Pac J Cancer Prev; 2012; 13(11):5563-8. PubMed ID: 23317218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONECUT2 upregulation is associated with CpG hypomethylation at promoter-proximal DNA in gastric cancer and triggers ACSL5.
    Seo EH; Kim HJ; Kim JH; Lim B; Park JL; Kim SY; Lee SI; Jeong HY; Song KS; Kim YS
    Int J Cancer; 2020 Jun; 146(12):3354-3368. PubMed ID: 32129880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers.
    Dai X; Sun X; Wu Y; Lv Z; Yu Z; Yuan Y; Sun L
    Dis Markers; 2022; 2022():4570290. PubMed ID: 35242243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
    Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
    World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.